Simponi Aria Alternatives Compared
Simponi Aria (golimumab) | Xeljanz (tofacitinib) | Methotrexate |
|
---|
Simponi Aria (golimumab) | Xeljanz (tofacitinib) | Methotrexate |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis. Simponi Aria may also be used for purposes not listed in this medication guide. View more |
Prescription only
Xeljanz is a Janus kinase (JAK) inhibitor that may be used to reduce inflammation associated with several conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, or... View more |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Rheumatoid Arthritis
Polyarticular Juvenile Idiopathic Arthritis
|
|||||||||||||||||||||||
More about Simponi Aria (golimumab) | More about Xeljanz (tofacitinib) | More about Methotrexate | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Simponi Aria has an average rating of 5.6 out of 10 from a total of 27 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 37% reported a negative effect. |
Xeljanz has an average rating of 5.7 out of 10 from a total of 145 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 40% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 335 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Simponi Aria side effects |
View all Xeljanz side effects |
View all Methotrexate side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Simponi Aria prices |
View all Xeljanz prices |
View all Methotrexate prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other golimumab brands include: Simponi | Other tofacitinib brands include: Xeljanz Oral Solution, Xeljanz XR | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
336 hours |
3 hours |
15 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 550 drugs are known to interact with Simponi Aria:
|
A total of 655 drugs are known to interact with Xeljanz:
|
A total of 716 drugs are known to interact with Methotrexate:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
November 06, 2012 |
December 07, 1953 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.